RGD-4C

RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models[1][2][3].

Product Specifications

CAS Number

[332179-76-7]

UNSPSC

12352209

Target

Integrin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rgd-4c.html

Purity

99.91

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CSSC[C@@H](C(N[C@H]1CC(O)=O)=O)NC([C@@H](N)C)=O)C(NCC(O)=O)=O)[C@@H](NC([C@@](CSSC[C@](C(N[C@H]2CCCNC(N)=N)=O)([H])NC1=O)([H])NC([C@@H](NC(CNC2=O)=O)CC(O)=O)=O)=O)CC3=CC=CC=C3

Molecular Formula

C42H60N14O16S4

Molecular Weight

1145.27

References & Citations

[1]Assa-Munt N, et al. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry. 2001 Feb 27;40 (8) :2373-8. |[2]Yin R, et al. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide. Bioconjug Chem. 2010 Jul 21;21 (7) :1142-7. |[3]Zuppone S, et al. A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer. Front Oncol. 2022 Apr 11;12:846958.